American Capital Advisory’s Roivant Sciences ROIV Stock Holding History

American Capital Advisory’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248	Hold	7	–	–	﹤0.01%	1051
2026 Q1	$194	Hold	7	–	–	﹤0.01%	1032
2025 Q4	$152	Buy	7 +5	+250%	+$99	﹤0.01%	948
2025 Q3	$31	Buy	+2	New	+$25	﹤0.01%	1000
2025 Q2	–	Sell	-19	Closed	-$192	–	976
2025 Q1	$192	Buy	+19	New	+$205	﹤0.01%	745

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

American Capital Advisory's ROIV Position: Q2 2026 in Review

American Capital Advisory held its Roivant Sciences (ROIV) position steady in Q2 2026 at 7 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

American Capital Advisory first reported a position in ROIV in Q1 2025 and has held it in 5 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

American Capital Advisory held 7 shares of Roivant Sciences worth $248 as of Q2 2026.
American Capital Advisory left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #1051 holding.
American Capital Advisory first reported a position in Roivant Sciences in Q1 2025 and has held it in 5 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.